News and Trends 9 Jun 2023 Quell in potential $2B AstraZeneca cell therapy deal Quell Therapeutics Ltd, a developer of engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, has entered into a collaboration, exclusive option and license agreement with AstraZeneca to develop, manufacture and commercialize autologous, engineered Treg cell therapies for two autoimmune disease indications. “We are extremely pleased to have AstraZeneca on […] June 9, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 8 Jun 2023 Acepodia raises $100M financing to boost cell therapies Acepodia, a clinical stage biotechnology company developing first-in-class cell therapies with its antibody-cell conjugation (ACC) and allogeneic gamma delta 2 T-cell platforms to address gaps in cancer care, has announced a $100 million Series D financing. The funds will be used to progress the company’s pipeline of enhanced cell therapies for solid tumors and hematologic […] June 8, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 8 Jun 2023 Kate Therapeutics launches with $51M to develop genetic medicines for muscle and heart diseases Gene therapy company Kate Therapeutics Inc. (KateTx), has emerged from stealth mode with a $51 million Series A financing. In addition, the company has granted Astellas Pharma Inc. an exclusive, worldwide license to develop, manufacture and commercialize KT430 to treat X-linked myotubular myopathy (XLMTM). There are a large number of genetically defined and complex muscle […] June 8, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 8 Jun 2023 Minoryx can start phase 3 trial for cerebral adrenoleukodystrophy patients Spanish-headquartered Minoryx Therapeutics says the U.S. Food and Drug Administration (FDA) has approved its phase 3 clinical trial (CALYX) of lead candidate leriglitazone, to treat adult male X-linked adrenoleukodystrophy (X-ALD) patients with cerebral adrenoleukodystrophy (cALD). X-ALD is an orphan neurodegenerative disease. The global incidence of X-ALD is approximately six to eight per 100,000 live births. […] June 8, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 7 Jun 2023 How Ireland connects AI and life sciences Depending on your point of view, artificial intelligence (AI) can create jobs, make life easier, and solve many global problems; or, it’s going to cause mass unemployment, take over the world, and enslave humanity. In the life sciences space, AI is capable of tackling some of the biggest challenges when it comes to tasks like […] June 7, 2023 - 7 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 7 Jun 2023 AAVantgarde closes €61M financing to move gene delivery program to the clinic AAVantgarde Bio, a clinical-stage, Italian-based international biotechnology company with two proprietary adeno-associated viral (AAV) vector platforms for large gene delivery, has closed a €61 million ($65.1 million) Series A financing. The amount represents the largest series A round ever in Italian biotech. AAVantgarde has two proprietary, AAV-based large gene delivery platforms: one leveraging DNA recombination, […] June 7, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
More News! 6 Jun 2023 $5.5M funding for Oncopole to tackle cancer Oncopole, Fonds de recherche du Québec – Santé (FRQS) cancer division in Canada, has received major investments that boost its public-private partnership model dedicated to the fight against cancer. Oncopole will continue to pursue its mission thanks to a $3 million reinvestment from founding partner Merck Canada. Oncopole, FRQS cancer division, is the result of […] June 6, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 6 Jun 2023 Head and neck cancer data presented at ASCO 2023 Results from promising trials in the fight against head and neck cancer have been presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago. Transgene, a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and NEC Corporation, a provider of IT, network and AI technologies, announced new […] June 6, 2023 - 7 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 6 Jun 2023 Shasqi using click chemistry to target cancer Shasqi, Inc., whose mission is to revolutionize cancer treatment with click chemistry, has entered into a research collaboration with Johnson & Johnson Enterprise Innovation Inc. Through the collaboration, Shasqi will apply its tumor-targeted Click Activated Protodrugs Against Cancer (CAPAC) platform to the development of new cancer therapies. Shasqi’s CAPAC platform relies on chemistry, not biology, […] June 6, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 5 Jun 2023 Rabies vaccine gets phase 3 trial approval YS Biopharma Co. Ltd.’s PIKA rabies vaccine has been granted phase 3 clinical trial approval from the Food and Drug Administration of the Philippines. The phase 3 clinical trial, which is planned to commence later in 2023, is a multi-center, multi-country study designed to evaluate the safety and immunogenicity of the vaccine. The study will […] June 5, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 5 Jun 2023 Bacterial resistance genes a ‘threat to human health’ Genes that make bacteria resistant to antibiotics are much more widespread in our environment than was previously realized. A new study, from Chalmers University of Technology and the University of Gothenburg in Sweden, shows that bacteria in almost all environments carry resistance genes, with a risk of them spreading and aggravating the problem of bacterial […] June 5, 2023 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Podcast 2 Jun 2023Beyond Biotech podcast 48 BioInvent International AB, a Swedish biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, and Transgene, a biotech company that designs and develops virus-based immunotherapeutics against cancer, recently announced positive phase 1a data on the oncolytic virus BT-001 for the treatment of solid tumors. BioInvent currently has four […] June 2, 2023 Share WhatsApp Twitter Linkedin Email